Iloprost infusion does not reduce oxidative stress in systemic sclerosis.
Systemic sclerosis is a connective tissue disease in which oxidative stress represents an important player among the complex pathogenetic mechanisms of the disease. Iloprost, an analogue of natural prostacyclin, is used in systemic sclerosis for the treatment of severe Raynaud's phenomenon and ischemic ulcers. There is a clear evidence that iloprost attenuates oxidative damage induced by ischemia-reperfusion phenomena. The aim of this study is to evaluate the effect of iloprost on oxidative status in ten patients with systemic sclerosis by measuring urinary levels of 8-isoprostaglandin-F(2alpha), a member of F(2)-isoprostanes. We found that systemic sclerosis patients cyclically treated with iloprost showed increased urinary level of 8-isoprostaglandin-F(2alpha )in comparison with healthy subjects; urinary 8-isoprostaglandin-F(2alpha) did not diminish soon after the iloprost infusion as well as 3, 15 and 30 days after the drug administration. Unlike experimental studies, in vivo the strong vasodilator effect of iloprost infusion did not reduce oxidative status.
Volpe
Alessandro
A
Department of Clinical and Experimental Medicine, University of Verona, P.le LA Scuro 10, 37134, Verona, Italy. reumatologia@sacrocuore.it
Biasi
Domenico
D
Caramaschi
Paola
P
Bambara
Lisa Maria
LM
Carletto
Antonio
A
Degan
Maurizio
M
Minuz
Pietro
P
D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D005260:Female; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation; D014665:Vasodilator Agents / Q000008:administration & dosage*
D014665:Vasodilator Agents; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; D016285:Iloprost
Prostaglandins Other Lipid Mediat. 2001 Jun;65(2-3):73-83
11403500
Prostaglandins Leukot Essent Fatty Acids. 2006 Jun;74(6):373-8
16687243
Rheumatology (Oxford). 2006 Mar;45(3):314-20
16219641
Br J Pharmacol. 1989 Oct;98(2):678-84
2479443
Joint Bone Spine. 2006 Jan;73(1):57-61
16253538
N Engl J Med. 2006 Jun 22;354(25):2667-76
16790699
Clin Exp Rheumatol. 1997 Mar-Apr;15(2):135-41
9196864
Ann Rheum Dis. 1992 Oct;51(10):1143-8
1332633
J Cardiovasc Surg (Torino). 2002 Oct;43(5):693-6
12386586
Cochrane Database Syst Rev. 2000;(2):CD000953
10796395
Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):279-86
15591226
N Engl J Med. 1985 Jan 17;312(3):159-63
2981404
Eur J Med Res. 2006 Jul 31;11(7):295-9
16899424
Arthritis Rheum. 2002 May;46(5):1319-23
12115239
Arthritis Rheum. 2001 Nov;44(11):2653-64
11710721
J Am Acad Dermatol. 1993 Jan;28(1):78-85
8425975
J Rheumatol. 1994 Aug;21(8):1477-83
7983650